INTRODUCTION
============

Gastritis refers to inflammation caused by damage to the epithelium of the stomach. The most common symptoms of gastritis include upper abdominal pain and nausea, vomiting, burping, and weight loss ([@ref8]). Chronic gastritis is associated with *Helicobacter pylori* infection, stress, or autoimmune diseases. Moreover, some types of gastritis caused by *H. pylori* infection progress to gastric ulcers and tumors ([@ref15]). Alternatively, acute gastritis is usually caused by excessive alcohol intake, long-term use of nonsteroidal anti-inflammatory drugs, and stress ([@ref6]; [@ref30]). Such irritation increases gastric acid secretion and damages the gastric mucosa ([@ref2]; [@ref23]). Gastric secretion pathways include activation of histamine H2 receptors (H2R) by histamine, activation of muscarinic acetylcholine receptor M3 (M3R) by acetylcholine, and activation of cholecystokinin 2 receptor (CCK2R) by gastrin. Activated H2R, M3R, and CCK2R increase cyclic adenosine monophosphate (cAMP) concentrations in parietal cells and activate H^+^/K^+^ ATPases. This increases the concentration of hydrochloric acid in gastric fluids, leading to gastric mucosal damage ([@ref24]; [@ref9]). Antacids, H2 receptor antagonists and proton pump inhibitors are used to treat gastritis by helping to minimize gastric mucosal damage caused by excessive gastric acid secretion ([@ref1]; [@ref32]; [@ref7]). However, the side effects and long-term burden of using these drugs are of increasing concern; therefore, there is a growing interest in promoting stomach health through healthier foods and natural compounds.

Mucins are the main components of mucus on the stomach's inner surface. Mucins are secreted though various mechanisms throughout the gastrointestinal, respiratory, female genital, and conjunctival mucosa systems ([@ref31]). Mucins have several physiological functions, including cell protection, mechanical protection, maintenance of viscosity in secretion, and cell recognition ([@ref33]). The structure of mucins have different compositional ratios depending on tissue type and disease ([@ref10]; [@ref34]; [@ref11]; [@ref21]). Previous studies have shown that the stomach expresses a unique mucin that provides protection against damage by low pH and protease digestion ([@ref31]). In addition, changes in mucin gene expression may affect functional dyspepsia ([@ref15]). Nine mucin genes are known to exist in humans, of which gastric- type mucins (MUC1, MUC5AC, and MUC6) are expressed in the human stomach ([@ref11]; [@ref21]; [@ref35]).

*Cudrania tricuspidata* is a deciduous tree used in traditional medicine to treat eczema, mumps, pulmonary tuberculosis, allergies, and acute arthritis ([@ref37]). Recent studies have reported that *C. tricuspidata* leaf, stem, root, and fruit extracts are effective in preventing diseases, such as liver damage, diabetes, arteriosclerosis, and obesity ([@ref27]; [@ref4]; [@ref12]; [@ref20]; [@ref17]; [@ref14]; [@ref3]; [@ref13]). In a previous study, we showed that ethanol extracts of *C. tricuspidata* leaves prevent reflux esophagitis in rats, which we predicted may be due to inhibition of H2R activity ([@ref18]). In addition, [@ref19] reported that *C. tricuspidata* leaf extract can protect against alcohol-induced gastric ulcers through their antioxidant activity. Although there is increasing evidence for the gastroprotective effects of *C. tricuspidata*, the molecular mechanisms underlying its biological activity remain unclear.

In the present study, we investigated the effects of *C. tricuspidata* ethanol extracts on gastric juice secretion, mucosal damage, and expression of acid secretion-associated genes in pylorus-ligated rats and primary parietal cells. We also measured the expression of gastric mucin genes following treatment with *C. tricuspidata* extracts. We aimed to provide evidence that *C. tricuspidata* ethanol extracts may protect gastric mucosa by inhibiting gastric cAMP and increasing mucin gene expression.

MATERIALS AND METHODS
=====================

Preparation of *C. tricuspidata* extract
----------------------------------------

*C. tricuspidata* extract powder was prepared as described in our previous study ([@ref18]). Briefly, dried *C. tricuspidata* leaves were ground to an appropriate size. Ethanol (70%; 10 times the weight of the leaves) was added to the extraction vessel, and the mixture was stirred at 50°C. The obtained extract was concentrated using a rotary vacuum evaporator (EYELA, Tokyo, Japan). The extract was then mixed with maltodextrin (corresponding to 50% of the solid content) and lyophilized to a powder. Rutin was used as an indicator compound, as described in a previous study ([@ref29]). Each dried material was re-suspended in 0.5% methyl cellulose (MC) dissolved in water for animal experiments or dimethyl sulfoxide for cell experiments.

Animals and treatment
---------------------

Seven-week-old male Sprague-Dawley rats were housed at a temperature of 21±2°C, relative humidity of 50±20 %, a ventilation frequency of 10∼15 times/h, and with 12 h of light per day (7:00 am to 7:00 pm). Breeding materials were disinfected before use, using a ultraviolet sterilizer. There were no abnormalities that could affect the test results during the experiment. All studies were approved by the Institutional Animal Care and Use Committee of KPC Co., Ltd. (approval number: P183005).

Rats were divided into four groups: vehicle administration group, ranitidine administration group, 5 mg/kg *C. tricuspidata* extract administration group, and 10 mg/ kg *C. tricuspidata* extract administration group. Rats were fasted for 24 h prior to receiving the test substance (*C. tricuspidata* extract or ranitidine), which was suspended in 0.5% MC. One hour after oral administration of the test substance, rats were anesthetized with isoflurane and the pylorus was ligated. After 8 h of operation, the rats were sacrificed with CO~2~ gas and stomachs were separated for experimentation. This animal study was performed using certification data for functional food approval.

Measurement of gastric secretion
--------------------------------

Gastric juice was collected from the rat stomachs, centrifuged at 800 *g* for 10 min, and the amounts of gastric juice (mL) were measured in the supernatants. To measure the total acidity of the gastric secretion, gastric juice (1 mL) was dispensed into tubes and titrated to pH 7.0 with 0.1 N NaOH; the amount of 0.1 N NaOH used for the titration was recorded. Total acidity was expressed in mEq, calculated using the formula below:

Total acidity (mEq)=amount of titrated NaOH (mL)× total gastric volume (mL)×0.1 N (correction of NaOH) ×50 (acidity factor)/ligation time (h)

Measurement of gastric mucosal damage
-------------------------------------

Stomachs drained of gastric juice were opened by incision at the greater curvature and photographed using a digital camera (Coolpix P5100, Nikon, Tokyo, Japan). Areas of gastric mucosal injury were measured using imaging software (Image Pro ver. 6.3, Media Cybernetics, Inc., Rockville, MD, USA).

Measurement of serum gastrin and histamine
------------------------------------------

Blood was collected before rats were sacrificed and centrifuged at 800 *g* for 30 min to extract the serum. Serum gastrin and histamine levels were measured using the rat gastrin I enzyme-linked immunosorbent assay (ELISA) kit and histamine ELISA kit (Abcam, Cambridge, UK) according to the manufacturer's instructions.

Measurement of gastric cAMP
---------------------------

Gastric mucosa isolated from rats was washed twice with phosphate buffer saline (PBS) and collected by centrifugation at 800 *g*. The gastric mucosa was treated with cAMP assay cell lysis buffer (R&D Systems, Minneapolis, MN, USA) and ground using a tissue homogenizer. The gastric mucosa suspension was centrifuged at 2,000 *g* and the supernatant was used to measure cAMP levels using a rat/mouse cAMP assay kit (R&D Systems).

Measurement of gene expression in gastric tissues
-------------------------------------------------

Total RNA was extracted from gastric mucosa using TRIzol reagent (Sigma-Aldrich Co., St. Louis, MO, USA) according to the manufacturer's instructions. cDNA was synthesized using the Reverse Transcription System (QIAGEN Sciences Inc., Germantown, MD, USA). The synthesized cDNA was subjected to real-time polymerase chain reaction (PCR) using the TaqMan Universal PCR master mix (Applied Biosystems, Foster City, CA, USA) and a QuantStudio 6 Real-Time PCR system (Applied Biosystems). TaqMan probe (Thermo Fisher Scientific, Waltham, MA, USA) used for mRNA expression analysis are presented in [Table 1](#T1){ref-type="table"}.

Parietal cell isolation and culture
-----------------------------------

Gastric parietal cells were isolated following the method of [@ref25]. Isolated stomach tissues were washed twice with PBS and incubated for in Dulbecco's modified Eagle's medium (DMEM) (Hyclone Laboratories, Logan, UT, USA) containing 20 mM hydroxyethyl piperazine ethane sulfonicacid (HEPES), collagenase (type 4, Worthington Biochemical Corp., Lakewood, NJ, USA) 1 mg/mL and bovine serum albumin (BSA) 1 mg/ mL for 30 min at 37°C. The cell suspensions was filtered through a cell strainers with 40 μM pores (BD Biosciences, Franklin Lakes, NJ, USA) and centrifuged at 1,000 *g* for 10 min. Isolated cells were suspended in DMEM/F-12 (GIBCO-BRL, Grand Island, NY, USA) containing 20 mM HEPES, 0.2% BSA, 10 mM glucose, insulin-transferrin-selenium-A, and 1 mM glutamine. This isolated gastric parietal cell suspensions were transferred into Corning^Ⓡ^Matrigel^Ⓡ^-coated plates (Corning Incorporated, Steuben County, NY, USA) and incubated at 37°C until use.

Measurement of gene expression in parietal cells
------------------------------------------------

After parietal cells were stabilized in Corning^Ⓡ^Matrigel^Ⓡ^- coated plates (Corning Incorporated) for 24 h, we added *C. tricuspidata* extracts or ranitidine with 100 μM of the H2R-specific agonist dimaprit (Sigma-Aldrich Co.) for 30 min. Cells were then collected to separate total RNA and synthesize cDNA. The cDNA was used as a template for real-time PCR to measure mRNA levels of H2R, M3R, and CCK2R. Reactions were carried out with TaqMan probes ([Table 1](#T1){ref-type="table"}) using a QuantStudio 6 Real-Time PCR system (Applied Biosystems).

Measurement of intracellular cAMP
---------------------------------

The medium of cultured parietal cells was replaced with DMEM/F-12 medium containing 10 μM RO-201724 (Sigma-Aldrich Co.) prior to treatment with test materials. The parietal cells were pretreated with *C. tricuspidata* extracts or 10 μM of ranitidine hydrochloride for 5 min, followed by 10 μM of the H2R specific agonist dimaprit (Sigma-Aldrich Co.) for 30 min. After 30 min of dimaprit treatment, parietal cells were treated with cAMP assay cell lysis buffer (R&D Systems) and immediately frozen. The frozen cells were disrupted by repeatedly freezing and thawing three times, centrifuged at 800 *g* for 15 min, and cAMP production was measured in the supernatant. cAMP assays were performed using the Rat/Mouse cAMP assay kit (R&D Systems).

Statistical analysis
--------------------

Experimental results were compared between groups using Minitab and one-way ANOVA, a parametric multiple comparison procedure. Results were expressed as mean± standard error (SE) and were considered statistically significant when *P*\<0.05.

RESULTS
=======

Effect of *C. tricuspidata* on pylorus ligation-induced gastric mucosal damage
------------------------------------------------------------------------------

Pylorus-ligated rat models ([@ref28]) were used to investigate the effects of *C. tricuspidata* extracts on gastric acid secretion and resulting gastric damage. In the vehicle group, gastric mucosa was damaged by gastric acid, resulting in redness. In contrast, in rats treated with ranitidine or *C. tricuspidata* extract there was a reduction in redness due to gastric acid secretion ([Fig. 1A](#F1){ref-type="fig"}). For the vehicle group, the area of gastric injury was 15.46±2.92 mm^2^. *C. tricuspidata* extracts at concentrations of 5 and 10 mg/kg attenuated the esophageal injury ratio to 9.09±2.13 mm^2^ and 6.37±1.82 mm^2^, respectively. Ranitidine at 7.7 mg/kg also reduced the area of gastric injury to 6.65±1.09 mm^2^ ([Fig. 1B](#F1){ref-type="fig"}). *C. tricuspidata* extract inhibited gastric mucosal damage in a dose-dependent manner, with the greatest reduction of gastric mucosal damage observed at 10 mg/kg.

Effect of *C. tricuspidata* on gastric acid secretion
-----------------------------------------------------

*C. tricuspidata* extracts decreased the total acidity of gastric juice in a concentration-dependent manner ([Table 2](#T2){ref-type="table"}). Furthermore, *C. tricuspidata* ethanol extracts reduced gastric acid secretion after pyloric ligatures, suggesting that *C. tricuspidata* extracts protect the gastric mucosa.

Effect of *C. tricuspidata* on gastric mucosa cAMP concentrations
-----------------------------------------------------------------

Gastric acid secretion is caused by activation of H2R, M3R, and CCK2R, which increase cAMP concentrations in parietal cells. Therefore, cAMP was measured in gastric mucosa to determine whether the acid-lowering effect of *C. tricuspid* extracts may be related to gastric cAMP. *C. tricuspidata* ethanol extracts reduced gastric cAMP in test animals in a concentration-dependent manner ([Fig. 2](#F2){ref-type="fig"}). Specifically, the extracts at 10 mg/kg inhibited cAMP activity to a similar extent as the H2R blocker, ranitidine.

Measurement of factors promoting gastric acid secretion
-------------------------------------------------------

To investigate factors that stimulate gastric cAMP production and gastric acid secretion, we measured mRNA levels of H2R, M3R, and CCK2R by real-time PCR, and serum gastrin levels by ELISA. Despite a slight degree of variation in the results, there were no significant differences in H2R, M3R, or CCK2R mRNA expression between the vehicle administration group and the *C. tricuspidata* extract administration groups ([Fig. 3A](#F3){ref-type="fig"}). Serum gastrin levels was unchanged by administration of *C. tricuspidata* extracts and slightly increased by ranitidine, although the difference was not significant ([Fig. 3B](#F3){ref-type="fig"}). The concentration of serum histamine did not vary between groups ([Fig. 3C](#F3){ref-type="fig"}).

Measurement of gastric mucin genes in gastric mucosa
----------------------------------------------------

The gastric mucus protects stomach tissues from stimulants such as gastric acid. Indeed, it has been reported that gastric ulcers caused by injury occur when the expression of MUC5AC or MUC6 genes in the gastric mucosa are reduced by *H. pylori* infection ([@ref36]; [@ref16]). The effect of *C. tricuspidata* extract on gastric mucus was investigated by measuring mRNA expression of MUC1, MUC5AC, and MUC6. Administration of *C. tricuspidata* extracts had no effect on MUC1 mRNA expression ([Fig. 4A](#F4){ref-type="fig"}), but increased mRNA expression of MUC5AC and MUC6 ([Fig. 4B and 4C](#F4){ref-type="fig"}).

*C. tricuspidata* inhibits H2R-mediated cAMP production in parietal cells
-------------------------------------------------------------------------

As described above, we showed that *C. tricuspidata* ethanol extracts inhibit gastric acid secretion and gastric mucosa injury by reducing gastric cAMP levels and increasing mucin gene expression. However, the mechanism by which *C. tricuspidata* inhibits gastric cAMP has not been elucidated. Therefore, to identify the mode of action of *C. tricuspidata* extracts, we measured the expression of genes related to gastric acid secretion and changes in cAMP levels after treatment of primary rat parietal cells with H2R agonists. Treatment of parietal cells with dimaprit, a selective H2R agonist, significantly increased levels of cAMP, which were inhibited by *C. tricuspidata* extracts in a dose-dependent manner ([Fig. 5A](#F5){ref-type="fig"}). However, *C. tricuspidata* only induced a, non-significant decrease in H2R mRNA expression ([Fig. 5B](#F5){ref-type="fig"}) and did not alter mRNA expression of the genes M3R and CCK2R involved in gastric secretion. Thus, *C. tricuspidata* was shown to reduce cAMP levels by inhibiting H2R activation rather than affecting mRNA expression.

DISCUSSION
==========

*C. tricuspidata* is known to be effective for treating gastrointestinal diseases in folk remedies. Many studies have reported the effects of *C. tricuspidata* on allergies, inflammation, liver damage, diabetes, and obesity ([@ref27]; [@ref22]; [@ref12]; [@ref20]; [@ref17]; [@ref14]; [@ref3]; [@ref13]), however the mechanism of action for treating gastroenteritic conditions such as gastritis remains unknown. Although the effect of *C. tricuspidata* extract on alcoholic gastric injury has previously been reported, only the antioxidant and anti-inflammatory effects of *C. tricuspidata* were described ([@ref19]). In our previous study, we showed that *C. tricuspidata* extracts inhibit increases in cAMP induced by H2R selective agonists in U937 monocytic cells ([@ref18]). However, the effects of *C. tricuspidata* on cAMP levels and expression of genes involved in gastric secretion in gastric mucosa and parietal cells were not confirmed. Therefore, in this study, we investigated whether *C. tricuspidata* extracts can protect gastric mucosa by reducing H2R-mediated cAMP production and increasing mucin genes in gastric mucosa of pylorus-ligated rats and primary parietal cells.

Oral administration of a single dose of *C. tricuspidata* ethanol extract reduced gastric acid-induced mucosa damage by reducing gastric cAMP and increasing mucin genes in pylorus-ligated animals ([Fig. 1](#F1){ref-type="fig"}, [Fig. 2](#F2){ref-type="fig"}, [Table 2](#T2){ref-type="table"}, and [Fig. 4](#F4){ref-type="fig"}). However, we did not observe any effects of *C. tricuspidata* on serum gastrin levels or gastric acid secretion-related genes, including H2R, M3R, and CCK2R ([Fig. 3A](#F3){ref-type="fig"}). Although serum gastrin appeared to increase following treatment with the H2R inhibitor ranitidine, it did not significantly differ between groups ([Fig. 3B](#F3){ref-type="fig"}). Treatment with H2R inhibitors increased serum gastrin, which is a reported side effect of inhibitors such as ranitidine and famotidine ([@ref5]; [@ref26]). In addition, serum histamine levels were not affected by the treatment ([Fig. 3C](#F3){ref-type="fig"}). These results suggest that reductions of gastric cAMP induced by *C. tricuspidata* extracts are not associated with mRNA expression of genes related to gastric acid secretion or levels of serum gastrin and histamine.

We therefore investigated whether *C. tricuspidata* inhibits H2R-mediated cAMP production in gastric parietal cells. In addition, we measured the effect of *C. tricuspidata* on mRNA expression of H2R, M3R, and CCK2R. We showed that *C. tricuspidata* ethanol extracts significantly inhibit cAMP production induced by H2R agonists, although only for a limited time ([Fig. 5A](#F5){ref-type="fig"}). However, this was not accompanied by any significant differences in the mRNA expression of H2R, M3R, or CCK2R ([Fig. 5B](#F5){ref-type="fig"}). Furthermore, *C. tricuspidata* ethanol extracts did not affect mRNA expression of the H^+^/K^+^ ATPase (data not shown). Overall, these results suggest that inhibition of gastric acid secretion by *C. tricuspidata* ethanol extract occurs by blocking binding of histamine to H2R.

In our previous and current studies, we showed that *C. tricuspidata* and its extracts are promising candidates for treatment of diseases associated with excessive gastric acid secretion, such as gastritis, gastric ulcer, and reflux esophagitis, acting via selectively inhibit H2R. Although several studies have been conducted to investigate the mechanism by which *C. tricuspidata* regulates gastric acid, none have investigated the increase in gastric mucin expression. Therefore, further studies are required to investigate the effect of *C. tricuspidata* on changes in mucin gene expression in mucosal tissues, including the stomach and intestines.

In conclusion, our data show that *C. tricuspidata* extracts can inhibit H2R and protect the gastric mucosa, thereby protecting against diseases such as gastritis and reflux esophagitis. Future studies should be conducted to confirm the effectiveness of *C. tricuspidata* in human clinical trials of individuals with heartburn and abdominal pain associated with excessive gastric acid. Moreover, this study may be used as a basis for further research on other effects of *C. tricuspidata* in the gastrointestinal tract.

**AUTHOR DISCLOSURE STATEMENT**

The authors declare no conflict of interest.

![Effect of *Cudrania tricuspidata* extracts on gastric mucosal damage. (A) Gastric lesions and (B) the area of gastric mucosal injury. Stomachs were collected immediately after rats were sacrificed and was dissected longitudinally from the greater curvature. The pylorus-ligated rats were treated with the indicated dose of *C. tricuspidata* extract. Veh, 0.5% methyl cellulose; Rani, 7.7 mg/kg of ranitidine; 5 mg/kg, 5 mg/kg of *C. tricuspidata* extract; 10 mg/kg, 10 mg/kg of *C. tricuspidata* extract. Values are mean±SE. Significantly different from the Veh group at \**P*\<0.05.](PNFS-25-158-f1){#F1}

![Effect of *Cudrania tricuspidata* extract on gastric gastric cyclic adenosine monophosphate (cAMP) levels. Gastric mucosa was collected from dissected stomachs, and cAMP levels were measured using cAMP detection kits. Pylorus-ligated rats were treated with the indicated dose of *C. tricuspidata* extract. Veh, 0.5% methyl cellulose; Rani, 7.7 mg/kg of ranitidine; 5 mg/kg, 5 mg/kg of *C. tricuspidata* extract; 10 mg/kg of *C. tricuspidata* extract. Values are mean±SE. Significant differences from the Veh group at \**P*\<0.05 and \*\**P*\<0.01.](PNFS-25-158-f2){#F2}

![Measurement of factors promoting gastric acid secretion in pylorus-ligated rats. (A) mRNA levels of muscarinic acetylcholine receptor M3 receptor (M3R), histamine H2-receptors (H2R), and cholecystokinin-2/gastrin receptors (CCK2R) in gastric mucosa. (B) Serum gastrin and (C) histamine levels in pylorus-ligated rats. mRNA was measured using cDNA synthesized from isolated gastric mucosa, and serum was collected before rats were sacrificed. The pylorus-ligated rats were treated with the indicated dose of *Cudrania tricuspidata* extract. Veh, 0.5% methyl cellulose; Rani, 7.7 mg/kg of ranitidine; 5 mg/kg, 5 mg/kg of *C. tricuspidata* extract; 10 mg/kg, 10 mg/kg of *C. tricuspidata* extract. Values are mean±SE.](PNFS-25-158-f3){#F3}

![Effect of *Cudrania tricuspidata* extract on gastric mucin gene expression. mRNA levels of (A) MUC1, (B) MUC5AC, and (C) MUC6 in gastric mucosa from pylorus-ligated rats. Rats were treated with the indicated dose of *C. tricuspidata* extract. Veh, 0.5% methyl cellulose; Rani, 7.7 mg/kg of ranitidine; 5 mg/kg, 5 mg/kg of *C. tricuspidata* extract; 10 mg/kg, 10 mg/kg of *C. tricuspidata* extract. Values are mean±SE. Significantly different from the Veh group at \**P*\<0.05 and \*\**P*\<0.01.](PNFS-25-158-f4){#F4}

![Effect of *Cudrania tricuspidata* extract on intracellular gastric cyclic adenosine monophosphate (cAMP) levels and gastric acid secretion related genes. (A) Intracellular cAMP levels in primary parietal cells stimulated by histamine H2-receptors (H2R) agonists. (B) H2R, muscarinic acetylcholine receptor M3 receptor (M3R), and cholecystokinin-2/gastrin receptors (CCK2R) mRNA expression in parietal cells treated with H2R agonists. Isolated primary rat parietal cells were pretreated with 10 μM of ranitidine or *C. tricuspidata* extracts for 5 min. Thereafter, cells were dstimulated with 100 μM Dimaprit. The control group was treated with the same amount of dimethyl sulfoxide. Values are mean±SE. ^\#^*P*\<0.01 indicates significant difference between the control group and the Dimaprit group. Significant difference are presented between the Dimaprit group and the *C. tricuspidata* extract groups at \**P*\<0.05 and \*\**P*\<0.01.](PNFS-25-158-f5){#F5}

###### 

TagMan probes used for qPCR

  Gene name                                          TaqMan^®^ probe ID   Dye
  -------------------------------------------------- -------------------- -----
  Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)   Rn01775763_g1        FAM
  Histamin receptor H2 (HRH2)                        Rn00564216_s1        FAM
  Muscarinic acetylcholine receptor M3 (M3R)         Rn00560986_s1        FAM
  Cholecystokinin 2 receptor (CCK2R)                 Rn00565867_m1        VIC
  Mucin 1 (Muc1)                                     Rn01462585_m1        VIC
  Mucin 5AC (Muc5AC)                                 Rn01451252_m1        FAM
  Mucin 6 (Muc6)                                     Rn01759814_m1        FAM

###### 

Effect of *Cudrania tricuspidata* on gastric juice volume and total acidity

  Group      Gastric juice volume (mL)                     Total acidity (mEq)                           pH
  ---------- --------------------------------------------- --------------------------------------------- -----------
  Veh        12.81±1.00                                    16.10±2.03                                    1.23±0.05
  Rani       7.82±0.69[\*\*](#t2f3){ref-type="table-fn"}   8.95±0.94[\*\*](#t2f3){ref-type="table-fn"}   1.30±0.03
  5 mg/kg    9.82±1.03                                     11.63±1.35                                    1.35±0.12
  10 mg/kg   9.06±0.84[\*](#t2f3){ref-type="table-fn"}     9.63±1.26[\*](#t2f3){ref-type="table-fn"}     1.32±0.06

Data were expressed as mean±SE.

The results were statistically analyzed by one-way ANOVA.

Significantly different from Veh at ^\*^*P*\<0.05 and ^\*\*^*P*\<0.01.

Veh, 0.5% methyl cellulose; Rani, 7.7 mg/kg of ranitidine; 5 mg/kg, 5 mg/kg of C. tricuspidata extract; 10 mg/kg, 10 mg/kg of *C. tricuspidata* extract.
